Comprehensive characterisation of the innovator product: Targeting bioequivalent generics

Journal of Generic Medicines

Volumn 2, Issue 4, 2005, Pages 335-346

  Koradia, Vishal S ^a,b   Chawla, Garima ^a   Bansal, Arvind K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b VIS Research Pvt Ltd   (India)

Author keywords

Generic; Innovator; Solid state characterisation; Therapeutic equivalence

Indexed keywords

EXCIPIENT; GENERIC DRUG; NEW DRUG; RANITIDINE;

ARTICLE; BIOEQUIVALENCE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; GRAVIMETRY; METHODOLOGY; PARTICLE SIZE; PHYSICAL DISEASE; PRESCRIPTION; SOLID STATE; TABLET FORMULATION;

EID: 23844518300     PISSN: 17411343     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jgm.4940086     Document Type: Article

References (21)

1. Jones, A.C. (2003) 'When in-licensing pays', Scrip Magazine, Vol. 123, pp. 13-15.
2. Milne, C.P. and Cairns, C. (2003) 'Generic drug regulation in the US under the Hatch-Waxman act. A balance between competition and innovation or confusion and intrigue?', Pharm. Dev. Regul., Vol. 1, pp. 11-27.
3. Jacob, W.F. and Kwak, Y.H. (2003) 'In search of innovative techniques to evaluate pharmaceutical R&D projects', Technovation, Vol. 23, No. 4, pp. 291-296.
4. Peny, J.M. (2003) 'How bright is the future for generics?', Scrip Magazine, Vol. 122, pp. 13-17.
5. Anon. (2004) 'Below average growth rates for top firms in 2003', SCRIP daily, April, pp. 1-3.
6. http://www.imshealth.com;
7. http://www.eyeforpharma.com, accessed in December 2004.
8. Bansal, A.K. and Koradia, V. (2004) 'Role of reverse engineering in the development of generic formulations', Pharm. Tech., (in press).
9. Physician's Desk Reference (2003) Thomson Montvale, NJ.
10. Nachaegari, S.K. and Bansal, A.K. (2002) 'High functionality excipient for solid dosage forms', Business Briefings, September, pp. 38-44.
11. Nachaegari, S.K. and Bansal, A.K. (2004) 'Coprocessed excipients for solid dosage forms', Pharm. Tech., Vol. 28, pp. 52-64.
12. Brittain, H.G., Bogdanowich, S.J., Bugay, D.E. et al. (1991) 'Physical characterization of pharmaceutical solids', Pharm. Res., Vol. 8, pp. 963-973.
13. Yamamura, S. and Momose, Y. (2001) 'Quantitative analysis of crystalline pharmaceuticals in powders and tablets by a pattern-fitting procedure using X-ray diffraction data', Int. J. Pharm., Vol. 212, pp. 203-212.
14. Stephenson, G.A., Forbes, R.A. and Reutzel-Edens, S.M. (2001) 'Characterization of the solid state: Quantitative issues', Adv. Drug Deliv. Rev., Vol. 48, pp. 67-90.
15. Brittain, H.G. (1999) 'Methods for the characterization of polymorphs and solvates', in Brittain, H.G. (Ed), 'Polymorphism in Pharmaceutical Solids', Marcel Dekker, New York, NY, pp. 228-278.
16. Carstensen, J.T. and Franchini, M.K. (1995) 'Isoenergic polymorphs', Drug Dev. Ind. Pharm., Vol. 21, pp. 523-536.
17. Burger, A. (1982) 'Thermodynamic and other aspects of the polymorphism of drugs', Pharm. Int. Vol. 3, pp. 158-163.
18. Cholerton, T.J., Hunt, J.H., Klinkert, G. and Smith, M.M. (1984) 'Spectroscopic studies on ranitidine - Its structure and the influence of temperature and pH', J. Chem. Soc. Perkin Trans. II, pp. 1761-1766.
19. Hohnjec, M., Kuftinec, J. and Malnar, M. (1986) 'Ranitidine', in Florey, K. (Ed), 'Analytical Profiles of Drug Substances', Academic Press, New York, NY, pp. 533-561.
20. Phadnis, N.V., Cavatur, R.K. and Suryanarayanan, R. (1997), 'Identification of drugs in pharmaceutical dosage forms by X-ray powder diffractometry', J. Pharm. Biomed. Anal., Vol. 15, pp. 929-943.
21. Raw, A.S., Furness, M.S., Gill, D.S. et al. (2004) 'Regulatory considerations of pharmaceutical solid polymorphism in abbreviated new drug applications (ANDAs)', Adv. Drug Deliv. Rev., Vol. 56, pp. 397-414.